牙齿这门生意，挺神奇。 一边是动辄几万元的隐形牙套，被贴上"精致消费升级"的标签；另一边却是价格战、需求放缓、监管收 紧，让整个赛道迅速降温。就在这种反差背景下，一家行业第三的国产隐形正畸企业再次启动IPO。近 日，据证监会披露，正雅齿科在浙江证监局完成IPO辅导备案。如果这是家普通企业，消息则会淹没在 每日数十条的备案新闻里，但它的特别之处就在于是国内隐形正畸市场的老三，仅次于国际巨头隐适美 和已上市的"牙套第一股"时代天使。 2003年，姚峻峰从英国赫尔大学MBA毕业。回国后，他没进投行，也没去外企，而是盯上了父亲所在 的医疗器械行业，创办正雅齿科。 事实上，这不是正雅第一次闯关IPO。2023年5月，正雅齿科就曾启动辅导备案，当时的辅导券商是中 金公司和国海证券，后来不了了之。此番卷土重来，辅导团队直接从"中金系"换成了"建投系"。要知 道，在投行圈这种临门一脚换保荐人的行为，通常意味着公司已经彻底抛弃了那种虚无缥缈的溢价幻 象，转而追求务实的过会确定性。 一 中金退出，建投接盘。 正雅齿科早在2023年5月就曾由"中金公司+国海证券"的组合保荐进行辅导，中金公司作为国内投行圈 的"贵族"，向来对项目要 ...

Core Insights - The article highlights the rapid growth of the invisible orthodontics brand "Times Angel" from Wuxi, which has become a leader in the global market, supported by a robust industrial cluster in the Huishan Economic and Technological Development Zone [1][2] Group 1: Industry Development - The Huishan Life Science Industrial Park, established in 2009, focused on the niche market of "digital orthodontics" rather than following the mainstream path, leading to the introduction of Times Angel as a key enterprise [2] - The park has attracted over 30 oral health-related companies, creating a complete industrial chain covering orthodontics, implants, restorations, materials, equipment, and services, forming the only full-chain dental industry cluster in the Yangtze River Delta [2][5] Group 2: Innovation and Collaboration - Continuous innovation is driven by a collaborative ecosystem that connects clinical needs with research and development, facilitated by partnerships with top institutions like Sichuan University and Shanghai Jiao Tong University [3] - The establishment of seven innovation platforms bridges the gap between local enterprises and leading clinical resources, enhancing the effectiveness of innovation [3] Group 3: Future Vision and Ecosystem - The Huishan region aims to integrate medical technology with consumer products, creating a collective brand image of "Oral Intelligence, Huishan Selection" [4] - A systematic ecological support framework is being developed, including specialized functional areas for R&D, testing, and consumer experience, alongside initiatives to attract social capital and cultivate technical talent in the dental industry [4][5]

Summary of the Conference Call on the Invisible Orthodontics Industry Industry Overview - The conference focused on the **invisible orthodontics industry**, particularly in the context of the Chinese market and the competitive landscape involving key players like **Angelalign**, **Invisalign**, and **Zhengya** [2][3]. Key Points and Arguments Market Growth and Trends - Initial expectations for the invisible orthodontics market in China were optimistic, with anticipated annual growth rates of at least **30%**. However, actual growth over the past two to three years has been slow, ranging from **0% to 10%**, with some years experiencing negative growth [2][3]. - Factors contributing to this slowdown include: - **Macroeconomic conditions** affecting consumer spending [2]. - **Increased competition** and **price reductions** due to collective procurement initiatives [3]. Competitive Landscape - The market is witnessing a **consolidation phase**, with smaller players exiting the market. For instance, a company named **Meilike** ceased operations, transferring its remaining cases to Angelalign and Zhengya, indicating a market cleanup [3]. - The top three companies dominate the market, with their combined market share exceeding **90%**. The ranking is as follows: 1. **Angelalign** 2. **Zhengya** 3. **Invisalign** [4]. Market Share Dynamics - **Invisalign's** market share has been declining, primarily due to competitive pressures and collective procurement initiatives. It was noted that **Invisalign** abandoned a bid during a collective procurement in **October 2022**, resulting in a loss of public hospital market share [4][5]. - Projections for market share in **2025** estimate: - Angelalign: **35%** - Zhengya: **25-30%** - Invisalign: **20%** [5]. Future Growth Projections - The overall market is expected to grow by **5-10%** in the coming years, driven by: - Increased adoption of invisible orthodontics among children and teenagers. - A shift from traditional braces to invisible aligners among adults due to lower prices [6]. - The **2026 collective procurement** is a critical factor that could impact pricing and market dynamics [7]. International Market Insights - Angelalign's international sales are projected to grow significantly, with estimates of **25,000 to 27,000 cases** in **2025**, up from **14,000** in **2024** [8]. - The international market has historically been dominated by **Invisalign**, but Angelalign is gaining traction due to its competitive pricing and service offerings [9][10]. Profitability and Cost Structure - The company's gross margin in China has been declining due to price competition, while margins in international markets are expected to improve as they focus on mid-to-high-end products [13][14]. - The anticipated gross margin in international markets is expected to be higher than in China due to better pricing strategies and product positioning [14]. Legal and Patent Issues - Angelalign is currently facing patent infringement lawsuits from **Invisalign** in multiple regions, including the U.S. and Europe. However, the company denies any infringement and is actively defending itself [15][16]. - Historical data suggests that such lawsuits have a low success rate in preventing market entry for competitors [16]. Additional Important Insights - The conference highlighted the importance of monitoring the **2026 collective procurement** and its potential impact on pricing strategies [7]. - The competitive landscape is shifting, with Angelalign and Zhengya expected to continue gaining market share at the expense of Invisalign [17]. - The overall sentiment is cautiously optimistic, with expectations of gradual recovery and growth in the invisible orthodontics market as economic conditions improve [17].

Group 1 - The Chengdu Enjoy Life Expo and Rongcheng Shopping Season commenced on September 19, attracting significant attendance and interest from various sectors, particularly in jewelry and oral health [1][5] - The jewelry exhibition area saw a large number of external buyers, with one vendor reporting over 100,000 yuan in orders within the first few hours [5] - The oral health section was also popular, with many young attendees seeking consultations, indicating a strong consumer focus on appearance management [5] Group 2 - The expo featured an innovative "dual scene" model, incorporating an outdoor experience area in Gui Xi Eco Park, appealing to families looking for a combination of shopping and leisure [9] - The event will run until September 21, focusing on key consumer sectors such as maternity and baby products, tourism, jewelry, and oral health, with over 260 exhibitors and an exhibition area exceeding 30,000 square meters [9] - In addition to the exhibition, a series of themed salons and health lectures will be held concurrently, enhancing the overall experience for attendees [9]

Core Viewpoint - The medical device sector is expected to witness a performance turning point from the second half of 2025 to 2026, driven by the continuous improvement in the technological strength and product competitiveness of domestic medical device companies, transitioning from "domestic substitution + penetration enhancement" to "international expansion + technological innovation" [2] Group 1: Policy Improvement and Industry Recovery - Historical performance shows a continuous decline in the medical device sector from 2021 to 2024, with further pressure in 2023-2024 due to upgraded medical compliance requirements and a slowdown in equipment renewal [3] - Signals of recovery are emerging, particularly in high-value consumables, where policy optimization is driving valuation recovery and there is significant room for penetration improvement [4] - In the medical equipment sector, a turning point in bidding growth is expected in Q4 2024, with leading companies' performance stabilizing and accelerating domestic substitution by Q3 2025 [5] - The in vitro diagnostics (IVD) sector is currently under policy pressure, but the chemical luminescence field may stabilize in terms of volume and price by Q4 2026, with significant potential for domestic substitution in the medium to long term [6] - For low-value consumables, attention is needed on overseas production capacity layout and progress with major customer collaborations under tariff policies [7] - The home medical device market, including respiratory machines and continuous glucose monitoring (CGM), presents vast opportunities, with a focus on consumer sentiment and international expansion [8] Group 2: Corporate Strategic Transformation - Companies are focusing on cost reduction and efficiency improvement through large-scale production, process optimization, and supply chain management to maintain profit margins [9] - Technological innovation is key, with differentiated product layouts helping to mitigate procurement risks, and healthcare insurance policies providing longer release cycles for innovative devices [10] - The transformation in consumption patterns shows that the impact of healthcare cost control is minimal, while consumption upgrades drive growth in optional medical demand, indicating a higher market ceiling [11] - International breakthroughs are being made as domestic companies leverage cost and supply chain advantages to accelerate overseas expansion [12] - Mergers and acquisitions are being utilized to break through existing market ceilings and enter emerging fields such as surgical robots and brain-computer interfaces [13] Group 3: Global Leadership in Innovative Medical Devices - Several Chinese companies have achieved technological breakthroughs, leveraging population size, clinical data accumulation, and industrial chain advantages [14] - Notable achievements include the world's first full-body PET/CT by United Imaging, leading chemical luminescence detection speeds by Mindray and New Industries, and the FDA breakthrough designation for Sino Medical's intracranial stent [15] Group 4: Growth Path of Global Medical Device Leaders - The strategy of going global is shifting from domestic substitution to global competition, with local operations and factory construction driving high growth in overseas business [16] - Technological innovation is fueled by R&D investment, with some companies accelerating internationalization through a license-out model [17] - Mergers and acquisitions are seen as a pathway for Chinese companies to release global growth potential, drawing lessons from U.S. medical device giants [18] Group 5: Investment Opportunity Analysis - In the Hong Kong stock market, attention should be paid to companies with strong innovation attributes and license-out potential, as well as undervalued companies with sufficient cash reserves that may turn profitable from 2025 to 2027 [19] - In the A-share market, companies expected to see performance turning points in Q2-Q3 2025 should be monitored, along with those benefiting from optimized procurement policies and new medical technologies [20] - The Chinese medical device industry is transitioning from a "follower" to a "leader," with technological innovation and international expansion becoming core driving forces, positioning leading companies to become world-class benchmarks [20]

Core Viewpoint - The acquisition of a 35% stake in Hangzhou Shuyaqi Medical Technology Co., Ltd. by Times Angel (06699.HK) signifies a strategic move to enhance its position in the orthodontic market, targeting both mid-range and budget segments while leveraging Shuyaqi's resources for global expansion [1][4][9]. Group 1: Acquisition Details - Times Angel will hold a 35% stake in Shuyaqi, which was established only a month and a half prior to the acquisition, indicating a rapid strategic development in the orthodontic sector [1]. - The acquisition allows Times Angel to jointly control Shuyaqi with Hansfu, which previously owned 100% of Shuyaqi [1][2]. Group 2: Market Position and Strategy - Times Angel is the leader in China's invisible orthodontics market, with a total revenue of $269 million in 2024, reflecting a 28.2% year-on-year growth [2]. - The partnership with Shuyaqi enables Times Angel to fill gaps in the budget market, thus creating a comprehensive product matrix that caters to various consumer segments [4][7]. Group 3: Competitive Landscape - The Chinese invisible orthodontics market is characterized by a dual oligopoly, with Times Angel and Align Technology (Invisalign) dominating the high-end segment, while local brands like Shuyaqi compete aggressively in the mid-range [7][9]. - The acquisition is expected to strengthen Times Angel's competitive edge against both high-end and mid-range competitors, allowing it to capture a larger market share [7][8]. Group 4: Global Expansion Potential - The global invisible orthodontics market is projected to grow from $6.5 billion in 2024 to $32.35 billion by 2030, with a compound annual growth rate (CAGR) of 30.7% [9]. - Times Angel's international revenue reached $80.55 million in 2024, accounting for 30% of its total revenue, indicating a significant push towards global markets [9]. Group 5: Technological Synergy - The collaboration between Times Angel and Hansfu is expected to enhance technological capabilities, particularly in digital orthodontic solutions, benefiting from Hansfu's expertise in dental scanning and 3D printing [5][8]. - Times Angel's investment in its iOrtho digital platform supports innovative features like "smile simulation," which can be further enhanced through the partnership with Shuyaqi [5][8].

Core Viewpoint - LuxCreo has achieved significant advancements in 3D printing technology for dental applications, particularly with the direct 3D printing of invisible braces, which has received regulatory approval in multiple countries, enhancing production efficiency and patient satisfaction [2][3]. Group 1: 3D Printing Technology in Healthcare - The potential of 3D printing in the medical field surpasses traditional manufacturing methods, enabling seamless integration of patient needs with advanced production techniques [2]. - LuxCreo's direct 3D printing of invisible braces eliminates the need for dental molds, significantly improving production efficiency and product accuracy, with the entire process taking only 3 hours from scanning to delivery [2]. - The collaboration with EMA Sleep aims to produce 3D printed medical devices for obstructive sleep apnea, addressing the limitations of traditional manufacturing methods and enhancing customization for patients [3]. Group 2: Market Potential and Competitive Advantage - The medical market is currently valued at $500 billion and is projected to grow to $800 billion by 2032, indicating substantial growth opportunities [3]. - LuxCreo positions itself as a leader in polymer 3D printing solutions by integrating advanced printers, AI software, and high-performance materials, providing a comprehensive digital production solution that gives it a competitive edge over traditional manufacturing methods [3]. Group 3: Upcoming Events and Industry Engagement - LuxCreo will participate in the 2025 (Fourth) Polymer 3D Printing Materials Summit, where its CTO will present on the mechanisms and applications of ActiveMemory™ smart materials in direct 3D printing of orthodontic devices [1][7].